том 39 издание 9 страницы 1760-1762

2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol- 5-yl)methyl)morpholine (1):  A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist

Тип публикацииJournal Article
Дата публикации1996-01-01
scimago Q1
wos Q1
БС1
SJR1.801
CiteScore11.5
Impact factor6.8
ISSN00222623, 15204804
Drug Discovery
Molecular Medicine
Найдено 
Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.

Топ-30

Журналы

1
2
3
4
5
6
7
8
9
Bioorganic and Medicinal Chemistry Letters
9 публикаций, 14.29%
Journal of Organic Chemistry
4 публикации, 6.35%
European Journal of Pharmacology
4 публикации, 6.35%
Tetrahedron
3 публикации, 4.76%
Journal of Medicinal Chemistry
3 публикации, 4.76%
Synthetic Communications
3 публикации, 4.76%
Tetrahedron Asymmetry
2 публикации, 3.17%
Journal of Pharmaceutical and Biomedical Analysis
2 публикации, 3.17%
Nature Communications
2 публикации, 3.17%
Handbook of Experimental Pharmacology
2 публикации, 3.17%
Progress in Medicinal Chemistry
2 публикации, 3.17%
Beilstein Journal of Organic Chemistry
1 публикация, 1.59%
Neuropeptides
1 публикация, 1.59%
Current Organic Chemistry
1 публикация, 1.59%
Tetrahedron Letters
1 публикация, 1.59%
Drug Discovery Today
1 публикация, 1.59%
Collection of Czechoslovak Chemical Communications
1 публикация, 1.59%
Molecules
1 публикация, 1.59%
Russian Chemical Bulletin
1 публикация, 1.59%
Mendeleev Communications
1 публикация, 1.59%
European Journal of Organic Chemistry
1 публикация, 1.59%
Chemistry - An Asian Journal
1 публикация, 1.59%
Biomedical Chromatography
1 публикация, 1.59%
Organic Process Research and Development
1 публикация, 1.59%
Journal of Chemical Information and Modeling
1 публикация, 1.59%
Organic Letters
1 публикация, 1.59%
Journal of the American Chemical Society
1 публикация, 1.59%
Green Chemistry
1 публикация, 1.59%
RSC Advances
1 публикация, 1.59%
1
2
3
4
5
6
7
8
9

Издатели

5
10
15
20
25
30
Elsevier
30 публикаций, 47.62%
American Chemical Society (ACS)
11 публикаций, 17.46%
Springer Nature
5 публикаций, 7.94%
Taylor & Francis
4 публикации, 6.35%
Wiley
3 публикации, 4.76%
Royal Society of Chemistry (RSC)
3 публикации, 4.76%
Beilstein-Institut
1 публикация, 1.59%
Bentham Science Publishers Ltd.
1 публикация, 1.59%
Institute of Organic Chemistry & Biochemistry
1 публикация, 1.59%
MDPI
1 публикация, 1.59%
Cambridge University Press
1 публикация, 1.59%
The Japan Institute of Heterocyclic Chemistry
1 публикация, 1.59%
5
10
15
20
25
30
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
63
Поделиться
Цитировать
ГОСТ |
Цитировать
Hale J. J. et al. 2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol- 5-yl)methyl)morpholine (1): A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist // Journal of Medicinal Chemistry. 1996. Vol. 39. No. 9. pp. 1760-1762.
ГОСТ со всеми авторами (до 50) Скопировать
Hale J. J., Mills S. G., MacCOSS M., Shah S. K., Qi H., Mathre D. J., CASCIERI M. A., Sadowski S., Strader C. D., MacIntyre D. E., Metzger J. M. 2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol- 5-yl)methyl)morpholine (1): A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist // Journal of Medicinal Chemistry. 1996. Vol. 39. No. 9. pp. 1760-1762.
RIS |
Цитировать
TY - JOUR
DO - 10.1021/jm950654w
UR - https://doi.org/10.1021/jm950654w
TI - 2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol- 5-yl)methyl)morpholine (1): A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist
T2 - Journal of Medicinal Chemistry
AU - Hale, Jeffrey J.
AU - Mills, Sander G.
AU - MacCOSS, MALCOLM
AU - Shah, Shrenik K.
AU - Qi, Hongbo
AU - Mathre, David J.
AU - CASCIERI, MARGARET A.
AU - Sadowski, Sharon
AU - Strader, Catherine D
AU - MacIntyre, D. Euan
AU - Metzger, Joseph M
PY - 1996
DA - 1996/01/01
PB - American Chemical Society (ACS)
SP - 1760-1762
IS - 9
VL - 39
PMID - 8627597
SN - 0022-2623
SN - 1520-4804
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{1996_Hale,
author = {Jeffrey J. Hale and Sander G. Mills and MALCOLM MacCOSS and Shrenik K. Shah and Hongbo Qi and David J. Mathre and MARGARET A. CASCIERI and Sharon Sadowski and Catherine D Strader and D. Euan MacIntyre and Joseph M Metzger},
title = {2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol- 5-yl)methyl)morpholine (1): A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist},
journal = {Journal of Medicinal Chemistry},
year = {1996},
volume = {39},
publisher = {American Chemical Society (ACS)},
month = {jan},
url = {https://doi.org/10.1021/jm950654w},
number = {9},
pages = {1760--1762},
doi = {10.1021/jm950654w}
}
MLA
Цитировать
Hale, Jeffrey J., et al. “2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol- 5-yl)methyl)morpholine (1): A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist.” Journal of Medicinal Chemistry, vol. 39, no. 9, Jan. 1996, pp. 1760-1762. https://doi.org/10.1021/jm950654w.